SAB Biotherapeutics Inc

NASDAQ:SABS   3:59:51 PM EDT
1.94
+0.11 (+6.01%)
Earnings Announcements

SAB Biotherapeutics Reports Q1 EPS Of $0.02

Published: 05/12/2022 20:27 GMT
SAB Biotherapeutics Inc (SABS) - Phase 2 Data for Sab-185 Expected to Be Available Later This Year.
Sufficient Cash Anticipated to Operate Into 2023.
Full Data From Phase 2a Trial That Evaluated Sab-176 for Treatment of Seasonal Influenza Expected Q3 2022.
Q1 Earnings per Share $0.02.
Revenue is expected to be $12 Million
Adjusted EPS is expected to be -$0.13

Next Quarter Revenue Guidance is expected to be $12.43 Million
Next Quarter EPS Guidance is expected to be -$0.12

More details on our Analysts Page.